

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/gs-21-794	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The pCR (pathological complete response) rate of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, statistical analysis plan, informed consent form, clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since this data may be updated over time.
7	To whom will you share the data?	Researchers who are interested in this study.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy of different dual-target drugs in neoadjuvant therapy for HER2 positive breast cancer.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: lq19903849599@163.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.